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ABSTRACT 1 
Background 2 
Hypertension is an established risk factor for dementia. However, it is unclear whether there are 3 
differential effects of angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor 4 
blockers (ARB) on brain health. In human observational studies, the evidence for superiority of 5 
either agent remains unclear. 6 
Objective 7 
To compare brain atrophy and cognitive decline between people treated with ACEi or ARB.  8 
Methods 9 
Participants aged 55-90 years without dementia had brain magnetic resonance imaging and 10 
neuropsychological assessments performed at 3 time points. The sample was enriched with 11 
people with Type 2 diabetes (T2D). Multivariable mixed models were used to examine 12 
longitudinal associations of AHM class with change in cognition and total brain volume.  13 
Results 14 
Of 565 people with longitudinal data, there were 163 on ACEi (mean age 69.9 years, T2D:64% 15 
with) and 125 on ARB (mean age 69.6 years, T2D:62%) at baseline. The baseline characteristics 16 
of those taking either an ACEi or ARB were similar with regards to age, sex, blood pressure 17 
control and vascular risk factors. The mean duration of follow up was 3.2 years. The baseline 18 
association of ACEi and ARB use with total brain volume was similar in both groups. However, 19 
those taking an ARB had a slower rate of brain atrophy than those taking an ACEi (p=0.031). 20 
Neither ACEi nor ARB use was associated with baseline cognitive function or cognitive decline.  21 
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Conclusions 1 
These results support the theory that ARB may be preferable to ACEi to reduce brain atrophy. 2 
The mechanisms underlying this differential association warrant further investigation. 3 
 4 
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INTRODUCTION 1 
High blood pressure is an established risk factor for the development of dementia [1]. Results 2 
from human observational studies and secondary observations in clinical trials of populations 3 
with high cardiovascular morbidity generally favour a beneficial effect of antihypertensive 4 
medications (AHM) on reducing dementia risk [2] but are not conclusive [3]. These studies 5 
report a wide variation in the magnitude of treatment effect [2, 4]. One possible explanation for 6 
this may be that various classes of AHM have differential effects on brain health independent of 7 
their blood pressure lowering effect [2, 4, 5].  8 
The Renin Angiotensin System (RAS) has been implicated in the development of cognitive 9 
decline [4, 6, 7]. Post-mortem studies reported an association between angiotensin converting 10 
enzyme and Alzheimer’s disease almost 40 years ago [8, 9] and were further supported by 11 
angiotensin I-converting enzyme gene association studies at the end of the last century [10]. A 12 
recent literature review reported that six out of seven identified human cohort studies described a 13 
trend for Angiotensin Converting Enzyme Inhibitor (ACEi) agents to be associated with a 14 
reduced risk of cognitive decline or dementia [2].  In the same review [2], four out of eight 15 
studies reported that Angiotensin II Receptor Blockers (ARB) were associated with a reduced 16 
risk of cognitive decline or dementia. The results from animal studies suggest that the location of 17 
interruption of the RAS may be important in modifying dementia risk but this is yet to 18 
demonstrated in human studies [6]. Amyloid beta protein (β-amyloid), important in dementia 19 
development is degraded by Angiotensin Converting Enzyme (ACE) [11, 12]. It may be that 20 
ARBs, that block RAS but do not inhibit the potentially beneficial action of ACE may be 21 
particularly advantageous [13]. Although results from basic science research seemed to support 22 
this theory, those from human studies remain inconclusive [2, 4] with recent observational 23 
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studies reporting a larger beneficial effect of ARB use on the risk of dementia than ACEi [14-1 
16]. A potential limitation of human studies to date is that many were designed to examine 2 
neurocognitive measures as only secondary outcomes within the context of large-scale trials of 3 
cardiovascular disease, and therefore lacked sensitive and detailed neuropsychological testing or 4 
volumetric imaging measures of brain structure. To address these limitations, a number of 5 
clinical trials, mainly recruiting people with established Alzheimer’s disease or Mild Cognitive 6 
Impairment have commenced to better understand the role of AHM [6].  7 
The aim of this study was to compare differences in brain atrophy and cognitive decline between 8 
people taking ACEi and ARB using data from a community-dwelling sample of older people 9 
enriched with type 2 diabetes (T2D), as RAS agents are more commonly used in T2D.  10 
MATERIALS AND METHODS 11 
Study population 12 
The sample was derived from two prospective cohort studies conducted concurrently within the 13 
same source population in Southern Tasmania (postcodes 7000-7199). In the first cohort, the 14 
longitudinal population-based Tasmanian Study of Cognition and Gait (TASCOG), people ≥ 60 15 
years were randomly selected from the Southern Tasmanian electoral roll between December 16 
2004 and 2010[17]. In the second cohort, the longitudinal Cognition and Diabetes in Older 17 
Tasmanians (CDOT), residents of Southern Tasmania with T2D aged ≥ 55 years were recruited 18 
from the National Diabetes Service Scheme between January 2008 and January 2010 [18]. The 19 
National Diabetes Service Scheme is a register of people with a confirmed diagnosis of T2D 20 
made by a physician using standard criteria (fasting plasma glucose ≥ 7.0 mmol/L, random 21 
plasma glucose ≥ 11.1 mmol/L, or 2-h glucose ≥ 11.1 mmol/L after oral glucose tolerance test).  22 
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The same definition was applied to TASCOG participants to confirm or exclude T2D status. 1 
Exclusion criteria were identical for both studies – being resident in a nursing home, insufficient 2 
English for cognitive testing or any contraindication to MRI scan. Both groups were followed up 3 
twice at approximately 2 and 4 years after baseline assessment. For this analysis, additional 4 
exclusion criteria included a history of dementia or Parkinson’s disease (determined by self-5 
report using a standardized questionnaire) [19]. Ethics approval was obtained from the Southern 6 
Tasmanian Health and Medical Human Research Ethics Committee and the Monash University 7 
Human Research Ethics Committee approved the study and informed written consent was 8 
obtained from all participants.  9 
Measurements 10 
All study measurements used in this analysis were collected in both cohorts using the same 11 
techniques and tools.   12 
BP and classification of AHM use 13 
Systolic and diastolic blood pressures (BP) were measured by an Omron M4 14 
sphygmomanometer and calculated as the mean of three consecutive seated brachial blood 15 
pressure measures from the right arm at each study review.  Each participant’s medication use 16 
was recorded by a nurse who sighted medications in a face-to-face interview to obtain an 17 
accurate list of medications actually taken by the participant. These medication lists were 18 
manually reviewed and classified according to drug type. Participants were first classified as 19 
being on any AHM (yes/no) and then as being any RAS (yes/no). Participants using RAS agents 20 
were classified further as either being on an ACEi or ARB.  21 
Cognitive function 22 
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A comprehensive battery of neuropsychological tests was used to measure cognition. (a)  Verbal 1 
fluency using the Controlled Word Association Test (COWAT, using the letters F, A, and S; 2 
Category Fluency (animals) [20]; (b) Executive function-interference with the Victoria Stroop 3 
test— using the color minus word sub-tests [21]; (c) Working memory: with the Digit Span 4 
subtest of the Wechsler Adult Intelligence Scale—Third Edition (WAIS-III) [22] (d) Attention-5 
processing speed—using the Victoria Stroop Dot tests, Symbol Search and Digit Symbol Coding 6 
subtests of the WAIS-III [22]; (e) Visuospatial ability—using the Rey Complex Figure copy task 7 
[20] (f) Verbal Memory—using the Hopkins Verbal Learning Test—revised  generating scores 8 
for total immediate recall, delayed recall, and recognition memory [20] and (g) Visual memory: 9 
with a delayed reproduction after 20 minutes of the Rey Complex Figure [20].  For each 10 
individual test we standardised scores at each visit by creating z scores using the mean and SD 11 
from the baseline visit. These domain scores were also averaged to create a global cognitive 12 
score and the average scores for each of the 7 listed cognitive domains. Domain scores with 13 
more than one cognitive test were re-standardized to a SD of 1. Similar to previous work [19, 23-14 
25], the re-standardized scores were used in the regression analysis to allow comparison of 15 
associations across cognitive domains. 16 
MRI Brain (total brain and lateral ventricular volume)  17 
Brain MRI prior to January 2011 was performed using a 1.5-Tesla scanner (LX Horizon, General 18 
Electric, Milwaukee, WI) using the following sequences: high-resolution T1-weighted spoiled 19 
gradient echo (repetition time (TR) 35 ms, echo time (TE)7 ms, flip angle 35°, field of view 20 
240×240 mm; voxel size 1 mm3) comprising 120 contiguous slices; fluid-attenuated inversion 21 
recovery (FLAIR) (TR 8,802 ms, TE 130 ms, inversion time 2200 ms; voxel size 0.50×0.50×3 22 
mm). MRI after January 2011 was performed using a new 1.5-Tesla scanner (Syngo, Siemens, 23 
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Erlangen, Germany) using the following sequences: high-resolution T1-weighted MPRAGE 1 
(TR=1910ms, TE=3.14ms, flip angle 15°, field of view 235×250mm; voxel size 1mm3) 2 
comprising 160 contiguous slices; FLAIR (TR=8500ms, TE=92ms, inversion time 2438ms; 3 
voxel size 0.9×0.9×3.5mm).  4 
T1-weighted and FLAIR scans for each patient were aligned using the co-registration facility of 5 
SPM12 (http://www.fil.ion.ucl.ac.uk/spm/). The FreeSurfer v5.3 longitudinal pipeline [26] was 6 
used to estimate total brain volume and intracranial volume. T2-weighted white matter 7 
hyperintensities (WMH) appear hypo-intense on T1-weighted scans and can be misclassified as 8 
gray-matter by FreeSurfer. Misclassifications were corrected using WMH masks generated from 9 
the co-registered FLAIR scans. Volume measures were calibrated between scanners by using a 10 
dataset of 11 participants imaged on both scanners. Two trained expert stroke physicians 11 
determined the presence of MRI infarcts and microbleeds at baseline. All image analyses were 12 
blinded to age, sex and cognitive outcome measures.  13 
Covariates 14 
Potential covariates included baseline age (centred to 55 years), sex, education (years) and self-15 
reported history of ever-smoking, myocardial infarct, hypercholesterolemia, hypertension and 16 
stroke. Additionally we included T2D (as previously defined) and ApoE4 genotype derived from 17 
whole blood DNA. 18 
Analysis 19 
Demographic and clinical between-group differences were examined using t-tests and Chi 20 
squared tests.  For longitudinal analyses, we used mixed models (mle, unstructured covariance) 21 
to examine the associations of baseline AHM use with change in MRI brain measures, global 22 
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cognitive function, and the individual cognitive domains.  Time since baseline measurement was 1 
the fixed effect and main effects were for AHM use and an interaction between AHM and time.  2 
Random effects for the intercept and slope were fitted for each individual, allowing participants 3 
to have different scores at baseline and rates of change in the dependent variable (MRI brain or 4 
cognitive measures). All models were adjusted for baseline age, sex, education, waist-hip ratio, 5 
T2D, ApoE4 carrier status (and intracranial volume for MRI measures). To examine whether the 6 
effect of AHM use was independent of BP, we further adjusted for baseline mean systolic and 7 
diastolic BP. Further exploratory analysis was subsequently performed for all classes of AHM 8 
and in those on AHM monotherapy with no AHM use as the reference group. Degrees of 9 
freedom (df) were calculated using the Kenward–Roger method [27]. Analysis was performed 10 
using STATA 15 (StataCorp LP College Station TX). 11 
RESULTS 12 
Of a baseline total sample of 711 participants, a further 4 participants with dementia and 2 13 
participants with Parkinson’s disease were excluded leaving a total of 705 participants at 14 
baseline. Cognitive data were available for 700 people (>98% of European decent) at baseline, 15 
504 at phase 2 and 431 at phase 3. Brain imaging data were available for 616 people at baseline, 16 
388 at phase 2 and 298 at phase 3. Table 1 describes the characteristics of those who had at least 17 
1 brain MRI available for analysis. Of these, 565 (80%) had at least one follow-up visit and 18 
contributed to further analyses. Within each of the drug use categories of no AHM, ACEi use 19 
and ARB use, the characteristics of people with or without brain imaging at each time point was 20 
broadly similar (Table 2).  21 
Comparison of ACEi and ARB use 22 
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A total of 163 people were taking an ACEi and 125 were taking an ARB on study entry. A total 1 
of 11 people were taking both ACEi and ARB and were excluded from analysis. The baseline 2 
characteristics of those taking either an ACEi or ARB were similar with regards to age, sex, 3 
blood pressure control and vascular risk factors and are described in detail in Table 1 and across 4 
time points in Table 2. Although those taking an ARB had lower baseline volume of white 5 
matter hyperintensities, and lower prevalence of brain infarct or microbleeds, these differences 6 
were not statistically significant (all p>0.19). The baseline association of ACEi and ARB use 7 
with total brain volume was similar in both groups (p for difference=0.99). However, adjusting 8 
for age, sex, T2D, education, blood pressure, waist-hip ratio and ApoE4 status there was an 9 
interaction between type of RAS inhibitor and brain atrophy over time, whereby those taking an 10 
ARB had a slower brain atrophy than those taking an ACEi (interaction β=2.06, df=152, 11 
p=0.031). The association of time (years) with brain volume was -6.7 (df=167, p<0.001). Figure 12 
1 displays the interaction between RAS agent and total brain volume change over time in the 13 
above model. The addition of baseline white matter hyperintensity volume, presence of brain 14 
infarcts and microbleeds to the above model resulted in minimal change (interaction β=2.03, 15 
p=0.033). Neither ACEi nor ARB use were associated with and baseline cognitive function or 16 
cognitive decline (Table 3). When stratified by diabetes status (i.e. repeating the analysis in the 17 
subgroup of people with T2D and then the subgroup of people without T2D), the above 18 
associations were no longer statistically significant (data not shown).  19 
Exploratory comparisons of different monotherapies  20 
Use of any blood pressure lowering agent 21 
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There were 368 people (mean age 70.2 years, SD 7.4) on at least one AHM and 198 not on any 1 
AHM (mean age 68.9 years, SD 7.3). The mean duration of follow up was 3.2 years. Compared 2 
with those not on AHM, and adjusted for age, sex, T2D, blood pressure, history of hypertension, 3 
ApoE4 status and BMI, people on AHM had lower total brain volume across all time points (β=-4 
10.98, 95%CI -20.31 to -1.66, df=541, p=0.021). However, using this same model, there was no 5 
interaction between use of a blood pressure lowering agent and time on total brain volume 6 
(p=0.31). Compared with those not on AHM, those taking at least one AHM had lower global 7 
(p=0.03), processing speed (p=0.008) and visuospatial function (p=0.006) across all time points 8 
(Table 3). There was an interaction between AHM use and time on verbal fluency scores, 9 
whereby those on AHM had a greater rate of decline in verbal fluency than those not on AHM 10 
(β=-0.05, p=0.007).  11 
Monotherapy 12 
Of those taking BP lowering medications, a total of 166 were taking a single medication (64  on 13 
ACEi, 45 on ARB, 24 on β-blocker, 18 on Calcium Channel Blocker (CCB), and 15 on diuretic). 14 
On study entry, those taking an ACEi had lower total brain volume than people not taking any 15 
hypertensives (β=-12.7, 95%CI -24.12 to -1.33, df=333, p=0.029) but there were no other 16 
statistically significant differences in total brain volume when comparing other monotherapies 17 
with no AHM treatment adjusting for age, sex, T2D, blood pressure, history of hypertension, 18 
ApoE4 status and BMI. There were no interactions between any of the BP lowering agents and 19 
time on brain volume (see Supplementary Figure 1). Supplementary Table 1 describes the 20 
associations of the different classes of AHM with the cognitive outcomes adjusting for baseline 21 
age, sex, education, systolic blood pressure, diastolic blood pressure, history of hypertension, 22 
waist hip ratio and ApoE4 status. At baseline, those taking an ACEi had poorer performance in 23 
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global (p=0.02), executive (p=0.04) and visuospatial function (p=0.02), those taking an ARB had 1 
poorer visuospatial function (0.02), those taking an β-blocker had poorer global (p=0.02), verbal 2 
(p=0.04) and executive function (p=0.004) and those taking a CCB had poorer processing speed 3 
(p=0.006) visuospatial function (p=0.02) and visual memory (p=0.01) but better executive 4 
function (0.01) than those not taking AHM. Those taking CCB had a greater rate of decline in 5 
verbal memory (0.003) than those not on BP lowering agents or taking other AHM.   6 
DISCUSSION 7 
In this sample, enriched with people with T2D, we found those taking an agent targeting the 8 
RAS had slower rates of atrophy than those on neither/no AHM. We also found that the use of 9 
ARB agents was associated with slower rates of brain atrophy than those taking ACEi, 10 
independent of blood pressure control. The size of this association was small, and the clinical 11 
significance of this association remains unclear. These results suggest that ARBs may have a 12 
beneficial effect on brain atrophy by mechanisms other than their blood pressure lowering effect.  13 
Similar to other studies [2], we report a possible beneficial effect of RAS inhibitors on brain 14 
ageing. Although there was a suggestion of beneficial effect of other AHMs, such as CCBs, we 15 
lacked the statistical power to have a high degree of confidence in these findings. Isolating the 16 
effects of other AHM is challenging in observational studies as many people require at least 2 17 
agents to successfully control blood pressure, and recent guidelines recommend 2 first-line 18 
agents for the management of stage 2 hypertension [28]. As such, the ability to analyse people 19 
using monotherapy is limited. Similarly, we lack the statistical power to sub-analyse the specific 20 
ACEi or ARB agent used. Making these distinctions is important as there are variations in the 21 
ACE catalytic domains of specific ACEi that affect β-amyloid degradation [6] and potentially 22 
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dementia risk. There are also within-class differences in blood brain barrier permeability in ACEi 1 
[29] and, to some degree, ARB [30] that require more understanding and may have important 2 
implications for dementia risk [6]. Supporting this, one observational study of 414 people (mean 3 
age 75 years) taking ACEi noted centrally acting ACEi use was associated with less cognitive 4 
decline and a lower rate of progression to dementia than peripherally acting ACEi [31]. Another 5 
study, using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset, reported the use 6 
of centrally acting ACEi and ARBs was associated with better memory performance than all 7 
other groups [32].  8 
Our finding that the use of any AHM and RAS inhibitors was associated with lower brain 9 
volume on study entry is likely related to the indication for AHM use. Such indications could 10 
include, but not be limited to, hypertension, T2D and chronic kidney disease. Our sample was 11 
enriched with people with T2D who, as described in previous work in this sample were more 12 
likely to be prescribed an ACEi or ARB and have better blood pressure control [18]. A sample 13 
enriched with people with T2D has the advantage of likely including more people taking RAS 14 
inhibitors but may come with heightened risk factor identification and management in a person 15 
with known high risk of vascular complications, limiting generalizability. If the indication for 16 
AHM explains the differences in brain volume seen on study entry then it is likely that this 17 
indication bias is removed by the mixed longitudinal modelling, allowing the isolation of the 18 
beneficial effect of both ACEi and ARB. This would explain our finding of between-group 19 
differences at baseline but the absence of a subsequent association with greater rates of cognitive 20 
or structural brain decline.  21 
To our knowledge, only one other study has examined the associations of RAS inhibition and 22 
longitudinal changes in brain volume [32]. This study used the ADNI dataset to compare 183 23 
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people with hypertension taking an ARB to people with hypertension taking any other AHM 1 
(n=621) and those with normal blood pressure (n=782). The authors found no between-group 2 
differences in brain volume change over three years but reported an association between 3 
centrally acting ACEi and ARB use and reduced WMH development in post hoc exploratory 4 
analysis. The between-agent differences we report may be the result of our sample having a 5 
larger burden of cerebrovascular disease and T2D than ADNI [32, 33] and a longer period of 6 
follow up with measurements at three time points providing additional statistical sensitivity to 7 
detect subtle changes. The benefits of including brain volume measures as an early marker of 8 
brain health are becoming increasingly recognized and are now beginning to be included as study 9 
outcome measures in AHM clinical trials [6, 34]. 10 
Although we report brain structural differences between groups, we did not find consistent 11 
cognitive differences. This lack of correlation between cognitive and brain structural measures 12 
may reflect the small effect size (~30% of the size of the effect of time) that may not be large 13 
enough to result in detectable cognitive changes. Future studies, over longer time periods are 14 
required to understand the clinical significance of the associations we report.  15 
Both vascular and neurodegenerative pathways have been implicated in explaining how ARB 16 
may have a beneficial effect on brain health. The specific targeting of ARB to Angiotensin II 17 
receptors (AT1 and possibly AT2) may result in greater vasodilation and improved cerebral 18 
blood flow than ACEi [35, 36]. Head-to-head studies comparing ACEi and ARB are lacking but 19 
results from animal models of stroke suggest that ARB may also have an anti-inflammatory 20 
action and neuroprotective role in humans [37, 38]. The results for a small number of studies 21 
suggest that ARB use is associated with lower AD pathology on autopsy [39] possibly via a 22 
beneficial effect on brain tau concentrations [40]. Supporting these observations, the ACE-23 
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sparing effect of ARBs may help preserve the proteolytic action of ACE on β-amyloid [11]. 1 
Future studies are required to confirm our findings taking advantage of advances in dementia 2 
biomarker development such as in-vivo neuroimaging of amyloid and tau as well as serum and 3 
cerebrospinal fluid analysis to better understand the mechanisms through which ARB may be 4 
beneficial. 5 
This study has a number of limitations. We followed people for a relatively short period of time 6 
and it may be that larger signals would be identified in cognition and brain structure over a 7 
longer period of time. We examined AHM use on study entry only and not for changes in 8 
medication use over time. Data regarding duration of exposure to AHM was unavailable in this 9 
study. As such we are unable to improve confidence in our results by exploring whether the 10 
duration of AHM use was associated with the size of the cognitive and structural associations we 11 
describe. Furthermore, the absence of this data prevents modelling of changes in AHM classes 12 
that commonly occur during an individual’s clinical management of hypertension. Clinical drug 13 
trials described in the review by Kehoe et al [6] are actively recruiting participants that will 14 
collect this data. Similar to other longitudinal studies, a proportion were lost to follow-up. Our 15 
analytical techniques allowed us to reduce the impact of different follow up periods for 16 
participants but does not completely eliminate this potential source of bias. Due to an 17 
unavoidable change in MRI scanner during our study period, we were unable to measure whether 18 
changes in white matter hyperintensity volume play a mediating or modifying role. Future 19 
studies, in cohorts with a larger burden of cerebrovascular disease may be able to further 20 
examine whether ARB have beneficial effects and explore if this is via more traditional 21 
cerebrovascular pathways. A further limitation associated with MRI scanner change was the loss 22 
of an ability to examine the regional distribution of brain volume loss. It would be of interest if 23 
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the regions of volume loss were consistent with the greater ACE activity seen in the medial 1 
hippocampal, parahippocampal, and temporal region in post-mortem studies of people with 2 
Alzheimer’s Dementia [8, 9].  Strengths of our study include the careful collection and 3 
classification of AHM use based on direct interview and use of a broad battery of neurocognitive 4 
tests and detailed serial brain MRIs allowing great sensitivity to detect subtle changes.  5 
In summary, those taking agents targeting RAS appear to have reduced volume loss compared to 6 
those not taking an AHM. ARB use may be associated with slower rates of brain atrophy than 7 
ACEi. There was no association between individual RAS inhibitor use and cognitive decline. 8 
The effect sizes we report are small, of uncertain clinical significance and may only manifest 9 
over long time periods.    10 
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Table 1 Sample characteristics at study entry 1 
 2 
Key: BP: AHM: Antihypertensive Medication; RAS: Renin Angiotensin System; ACEi: 3 
Angiotensin Converting Enzyme inhibitor; ARB: Angiotensin II Receptor Blocker; ApoE4: 4 
Apolipoprotein E4 carrier; MRI: Magnetic Resonance Imaging  5 
 ACEi ARB Other 
AHM 
No AHM Total 
n 163 125 69 198 565 
 Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) 
Age  69.9 (7.5) 69.6 (7.5) 72.2 (6.6) 68.9 (7.3) 69.8 (7.4) 
Years of formal education 
(yr) 
12 (3) 11 (3) 10 (3) 12 (4) 11.3 (3) 
Systolic blood pressure 
(mmHg) 
138 (21) 137 (20) 142 (21) 140 (20) 139 (20) 
Diastolic blood pressure  
(mmHg) 
78 (11) 77 (12) 78 (10) 80 (11) 78 (11) 
Body Mass Index (kg/m2) 30 (5) 30 (5) 28 (4) 27 (4) 29 (5) 
Waist Hip Ratio 0.95 
(0.08) 
0.95 
(0.08) 
0.93 
(0.09) 
0.91 
(0.09) 
0.93 
(0.09) 
Diabetes duration  (yr) 5 (9) 6 (10) 2 (5) 3 (6) 4 (8) 
White matter hyperintensity 
volume (ml) 
4.48 
(7.33) 
3.41 
(4.67) 
5.69 
(7.85) 
3.00 
(5.33) 
3.78 
(6.12) 
      
 n (%) n (%) n (%) n (%) n (%) 
Female Sex  67 (41) 60 (48) 36 (52) 84 (42) 255 (45) 
Type 2 Diabetes  104 (64) 78 (62) 25 (36) 72 (36) 287 (51) 
History of hypertension  163 (100) 125 (100) 69 (100) 105 (53) 473 (84) 
Angina  24 (15) 23 (18) 14 (20) 16 (8) 78 (14) 
Myocardial infarct  31 (19) 13 (10) 11 (16) 14 (7) 70 (12) 
Stroke  20 (12) 9 (7) 8 (12) 8 (4) 46 (8) 
High cholesterol  110 (67) 84 (67) 32 (46) 87 (44) 322 (57) 
Ever -smoker  79 (48) 68 (54) 34 (49) 109 (55) 294 (52) 
APoE4 carrier 42 (26) 32 (26) 14 (20) 50 (25) 141 (25) 
Insulin therapy  26 (16) 18 (14) 4 (16) 9 (13) 59 (10) 
Infarct on MRI  46 (28) 27 (22) 17 (25) 24 (12) 115 (20) 
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Table 2 Characteristics of participants and drop outs at each time point  1 
 Phase 1  Phase 2  Phase 3  
 Imaging 
available 
Imaging 
not 
available 
Imaging 
available 
Imaging 
not 
available 
Imaging 
available 
Imaging 
not 
available 
No AHM (n) 198 32 138 92 102 36 
 Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
 Age (yr) 68.9 
(7.3) 
70.1 
(7.3) 
68.6 
(7.0) 
69.8 
(7.6) 
67.8 
(6.8) 
70.9 
(7.4) 
Systolic blood pressure 
(mmHg) 
140 (20) 140 (18) 139 (18) 142 (21) 138 (17) 141 (21) 
Diastolic blood 
pressure (mmHg)  
80 (11)  81 (10) 80 (11) 81 (11) 80 (10) 81 (12) 
Body Mass Index 
(kg/m2) 
27 (4) 28 (5) 27 (4) 27 (4) 28 (4) 27 (4) 
Baseline total brain 
volume (ml)  
915 (88) N/A 916 (88) 912 (88) 919 (91) 909 (83) 
 n (%) n (%) n (%) n (%) n (%) n (%) 
Female sex 84 (42) 12 (38) 59 (43) 37 (40) 40 (39) 19 (53) 
ApoE4 carrier 50 (25) 9 (28) 34 (25) 25 (27) 23 (23) 11 (31) 
Type 2 diabetes 72 (36) 13 (41) 49 (36) 36 (39) 40 (39) 9 (25) 
ACEi (n) 163 37 96 104 77 19 
 Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
 Age (yr) 69.9 
(7.5) 
70.1 
(8.4) 
69.1 
(7.0) 
70.8 
(8.1) 
68.3 
(6.7) 
72.4 
(7.6) 
Systolic blood pressure 
(mmHg) 
138 (21) 136 (21) 134 (19) 141 (22) 135 (20) 132 (14) 
Diastolic blood 
pressure (mmHg)  
78 (11) 74 (12) 76 (10) 78 (12) 76 (11) 76 (7) 
Body Mass Index 
(kg/m2) 
30 (5) 33 (7) 30 (5) 31 (7) 29 (4) 31 (5) 
Baseline total brain 
volume (ml)  
894 (99) N/A 907 
(106) 
876 (86) 909 
(109) 
897 (96) 
 n (%) n (%) n (%) n (%) n (%) n (%) 
Female sex 67 (41) 14 (38) 33 (34) 48 (46) 25 (32) 8 (42) 
ApoE4 carrier 42 (26) 6 (16) 28 (29) 20 (19) 21 (27) 7 (37) 
Type 2 diabetes 104 (64) 27 (73) 64 (67) 67 (64) 53 (69) 11 (58) 
ARB (n) 125 17 79 63 60 19 
 Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
Mean 
(sd)  
 Age (yr) 69.6 
(7.5) 
70.1 
(6.9) 
68.3 
(6.7) 
71.3 
(8.1) 
68.5 
(6.7) 
68.0 
(6.6) 
Systolic blood pressure 137 (20) 133 (25) 135 (20) 137 (21) 136 (19) 135 (23) 
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(mmHg) 
Diastolic blood 
pressure (mmHg)  
77 (12) 72 (10) 78 (12) 75 (11) 77 (11) 78 (14) 
Body Mass Index 
(kg/m2) 
30 (5) 30 (4) 31 (5) 30 (4) 30 (6) 31 (5) 
Baseline total brain 
volume (ml)  
895 (96) N/A 906 
(101) 
876 (85) 908 
(103) 
903 (99) 
 n (%) n (%) n (%) n (%) n (%) n (%) 
Female sex 60 (48) 8 (47) 40 (51) 28 (44) 32 (53) 8 (42) 
ApoE4 carrier 32 (26) 5 (29) 20 (25) 17 (27) 14 (23) 6 (32) 
Type 2 diabetes 78 (62) 10 (59) 47 (59) 41 (65) 37 (62) 10 (53) 
Other AHM (n) 80 14 47 47 35 12 
 Age (yr) 71.7 
(6.7) 
75.1 
(6.1) 
71.5 
(7.2) 
73.0 
(6.2) 
70.3 
(7.1) 
75.1 
(6.4) 
Systolic blood pressure 
(mmHg) 
143 (22) 139 (22) 140 (20) 144 (24) 137 (17) 151 (28) 
Diastolic blood 
pressure (mmHg)  
77 (10) 77 (15) 77 (8) 78 (13) 77 (8) 77 (8) 
Body Mass Index 
(kg/m2) 
28 (4) 30 (7) 28 (5) 29 (5) 29 (4) 26 (5) 
Baseline total brain 
volume (ml)  
896 (88) N/A 888 (83) 906 (88) 893 (86) 873 (75) 
 n (%) n (%) n (%) n (%) n (%) n (%) 
Female sex 44 (55) 5 (4) 28 (60) 21 (45) 19 (54) 9 (75) 
ApoE4 carrier 17 (21) 4 (29) 11 (23) 10 (21) 8 (23) 3 (25) 
Type 2 diabetes 33 (41) 6 (43) 20 (43) 19 (40) 13 (37) 7 (58) 
Key: BP: AHM: Antihypertensive Medication; ACEi: Angiotensin Converting Enzyme inhibitor; 1 
ARB: Angiotensin II Receptor Blocker; ApoE4: Apolipoprotein E4 carrier; T2D: Type 2 2 
Diabetes 3 
  4 
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Table 3 Associations between blood pressure agent use and cognitive function 
   ACE vs 
ARB 
   Any AHM vs 
no AHM 
 
Cognitive z- 
scores 
β Degrees 
of 
freedom 
95%CI p-
value 
β Degrees 
of 
freedom 
95%CI p-
value 
Global cognitive 
z-score 
        
Agent 0.13 245 -0.05 to 0.31 0.17 -0.19 498 -0.37 to -0.02 0.027 
Agent x Time 0.01 171 -0.06 to 0.09 0.70 -0.02 329 -0.07 to 0.03 0.53 
Verbal fluency          
Agent 0.18 259 -0.04 to 0.39 0.10 -0.04 532 -0.25 to 0.16 0.68 
Agent x Time -0.004 150 -0.05 to 0.04 0.88 -0.05 292 -0.08 to 0.01 0.007 
Verbal memory         
Agent 0.10 252 -0.09 to 0.28 0.31 -0.10 522 -0.28 to 0.08 0.28 
Agent x Time -0.02 162 -0.08 to 0.33 0.49 -0.03 303 -0.07 to 0.01 0.20 
Processing 
speed 
        
Agent 0.05 259 -0.14 to 0.25 0.61 -0.26 527 -0.45 to -0.07 0.008 
Agent x Time -0.003 158 -0.04 to 0.04 0.89 -0.01 296 -0.03 to 0.016 0.49 
Executive 
function 
        
Agent 0.09 220 -0.09 to 0.27 0.32 -0.10 440 -0.27 to 0.06 0.21 
Agent x Time 0.04 196 -0.06 to 0.14 0.42 -0.01 368 -0.08 to 0.05 0.73 
Working 
memory 
        
Agent -0.001 259 -0.22 to 0.22 1.00 -0.20 533 -0.41 to 0.01 0.07 
Agent x Time 0.01 148 -0.04 to -
0.05 
0.81 -0.01 285 -0.05 to 0.02 0.43 
Visuospatial 
function 
        
Agent 0.05 254 -0.17 to 0.26 0.66 -0.26 533 -0.45 to -0.08 0.006 
Agent x Time -0.004 157 -0.08 to 0.07 0.90 0.03 301 -0.03 to 0.08 0.34 
Visual memory         
Agent -0.02 255 -0.22 to 0.17 0.82 -0.12 502 -0.26 to 0.03 0.12 
Agent x Time -0.05 157 -0.10 to 
0.005 
0.08 -0.02 305 -0.05 to 0.27 0.41 
Adjusted for baseline age, sex, education, systolic blood pressure, diastolic blood pressure, 
history of hypertension, waist hip ratio, ApoE4 status 
Key ACEi: Angiotensin Converting Enzyme inhibitor; ARB: Angiotensin II Receptor Blocker; 
AHM: Antihypertensive Medication   
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Figure 1. Associations between antihypertensive medication use and total brain volume over 
time. 
 
Key: Adjusted for baseline age, sex, education, systolic blood pressure, diastolic blood pressure, 
history of hypertension, waist hip ratio, ApoE4 status and total intracranial volume  
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Supplementary Material 
Supplementary Figure 1 Associations of AHM and brain volume at baseline and over time in 
those taking only one antihypertensive medication 
 
 Key: Adjusted for baseline age, sex, education, systolic blood pressure, diastolic blood pressure, 
history of hypertension, waist hip ratio, ApoE4 status and total intracranial volume 
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 ACEi ARB Β-blocker CCB Diuretic 
Brain Volume (ml) β (p value) β (p value) β (p value) β (p value) β (p value) 
Agent -16.31 
(0.01) 
-7.42 
(0.30) 
11.62 
(0.21) 
-8.53 
(0.42) 
1.75 
(0.87) 
Agent x Time -0.67 
(0.52) 
0.43 
(0.72) 
-0.43 
(0.80) 
-2.39 
(0.20) 
0.29 
(0.90) 
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Supplementary Table 1. Association between different antihypertensive medication use and 
cognitive function in people taking a single agent  
  ACEi ARB Β-
blocker 
CCB Diuretic 
Cognitive domain z 
scores 
 β (p 
value) 
β (p 
value) 
β (p 
value) 
β (p 
value) 
β (p 
value) 
Global cognition Agent -0.27 
(0.02)* 
0.01 
(0.92) 
-0.43 
(0.02)* 
-0.02 
(0.92) 
-0.17 
(0.43) 
 Agent x Time -0.03 
(0.37) 
0.02 
(0.62) 
0.01 
(0.85) 
0.06 
(0.42) 
-0.05 
(0.57) 
Verbal fluency Agent -0.04 
(0.81) 
-0.03 
(0.86) 
-0.14 
(0.51) 
-0.32 
(0.17) 
-0.11 
(0.66) 
 Agent x Time -0.05 
(0.09) 
-0.05 
(0.13) 
-0.08 
(0.10) 
-0.04 
(0.46) 
-0.07 
(0.28) 
Verbal memory Agent -0.11 
(0.36) 
0.02 
(0.91) 
-0.37 
(0.04)* 
-0.21 
(0.31) 
0.04 
(0.84) 
 Agent x Time 0.01 
(0.85) 
0.02 
(0.53) 
-0.10 
(0.08) 
-0.17 
(0.003)* 
0.01 
(0.86) 
Processing speed Agent -0.15 
(0.27) 
-0.21 
(0.16) 
-0.05 
(0.84) 
-0.60 
(0.006)* 
-0.36 
(0.12) 
 Agent x Time -0.004 
(0.84) 
-0.02 
(0.42) 
-0.003 
(0.91) 
0.01 
(0.80) 
0.01 
(0.80) 
Executive function Agent -0.22 
(0.04)* 
0.11 
(0.36) 
-0.45 
(0.004)* 
0.45 
(0.01)* 
-0.09 
(0.66) 
 Agent x Time -0.05 
(0.33) 
0.03 
(0.64) 
0.02 
(0.83) 
0.12 
(0.18) 
-0.04 
(0.69) 
Working memory Agent -0.15 
(0.34) 
-0.10 
(0.73) 
-0.27 
(0.24) 
-0.49 
(0.06) 
-0.14 
(0.60) 
 Agent x Time -0.01 
(0.74) 
0.03 
(0.35) 
-0.03 
(0.51) 
-0.06 
(0.23) 
-0.12 
(0.07) 
Visuospatial function Agent -0.29 
(0.02)* 
-0.33 
(0.02)* 
-0.23 
(0.21) 
-0.49 
(0.02)* 
0.04 
(0.84) 
 Agent x Time 0.04 
(0.38) 
0.08 
(0.10) 
-0.09 
(0.18) 
0.03 
(0.67) 
-0.02 
(0.84) 
Visual memory Agent -0.29 
(0.03)* 
-0.25 
(0.08) 
0.12 
(0.52) 
-0.55 
(0.01)* 
-0.01 
(0.98) 
 Agent x Time 0.01 
(0.73) 
-0.003 
(0.94) 
-0.09 
(0.08) 
-0.03 
(0.66) 
0.002 
(0.98) 
Adjusted for baseline age, sex, education, systolic blood pressure, diastolic blood pressure, 
history of hypertension, waist hip ratio and ApoE4 status  
Key ACEi: Angiotensin Converting Enzyme inhibitor; ARB: Angiotensin II Receptor Blocker; 
CCB: Calcium Channel Blocker. *p<0.05   
 
